Abstract:Background: Lung Cancer is the most common cancer in China. Brain metastasis(BM) is the main reason for treatment failure of advanced lung cancer and treatment strategy is unclear in real world practice. Recently, some data showed that EGFR-TKI was an efficient option for NSCLC BM patients. Further evidence on EGFR-TKI plus standard therapy in clinical practice is highly expected. Methods: Based on our clinical database, we collected the clinical data of patients diagnosed with NSCLC and BM during 2014 and 2017. The therapeutic effectiveness was compared between the chemoradiation and chemoradiation + EGFR-TKI. Log-rank test was used in the comparison of the two groups. Cox's proportional hazard models were used in the factor analyses. Results: Total 153 patients were analyzed in the study, 61 patients treated by chemoradiation and 92 patients by chemoradiation + EGFR-TKI. Baseline characters of age, location and T stage of primary disease, and metastatic numbers were balanced in two groups. Gefitinib is the most frequently used TKI in clinical practice, composing about 48%(44/92). In chemoradiation + EGFR-TKI, 72 patients were performed with EGFR gene test and of them, 56 patients (78%) were EGFR positive. In chemoradiation, 29 patients were performed with EGFR gene test and 2 patients (6.9%) were EGFR positive. EGFR positive rate was 57% (58/101) in the total patients. The OS trend obviously showed that patients got more advantage from chemoradiation + EGFR-TKI compared with chemoradiation. Median OS was 27.0 months in the chemoradiation + EGFR-TKI and 16.6 months in the chemoradiation. Subgroup 24 months survival rate analysis of Gefitinib vs other TKI is 0.732 and 0.427, p = 0.0124. This preliminary analysis indicated that adding TKI to chemoradiation treatment could improve OS (hazard ratio [HR] 1.887) on NSCLC BM patients. Conclusions: The first analysis presents the survival benefit of EGFR-TKI plus standard treatment on NSCLC BM patients. Further data from this real-world study will be generated as we continue recruiting more patients in near future. Legal entity responsible for the study: Oncology Department, Tangdu Hospital affiliated with the PLA Airforce Medical University Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest.

Effect Analysis of EGFR Gene Mutation and Autologous CIK Cell Immunotherapy Combined with Sequential Radiotherapy in Treatment of Lung Cancer Associated by Bone Metastasis

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in Egfr Mutation/Alk Translocation Metastatic Non-Small Cell Lung Cancer

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Correlation of CA-simple Sequence Repeat Polymorphism of Epidermal Growth Factor Receptor Gene with Clinical Outcome of Patients with Advanced Non-Small Cell Lung Cancer after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

Comparison of clinical outcome and efficacy of patients with advanced non-small cell lung cancer Harbouring different epidermal growth factor receptor mutations

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Association of CD8 T cell apoptosis and <i>EGFR</i> mutation in non-small lung cancer patients

Effect of gene mutation of epidermal growth factor receptor on targeting therapy of advanced non-small cell lung cancer

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer

EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis

211P First Analysis of a Real-World Study to Explore the Character and Treatment Outcome of Epidermal Growth Factor Receptor (Egfr)-Tyrosine Kinase Inhibitor (TKI) on Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases (BM)

Effect of Gene Mutations of Epidermal Growth Factor Receptor on the Maintenance Therapy of Advanced Non-Small Cell Lung Carcinoma

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations

Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations

EGFR-TKIS Combined with Radioactive 125I Seed Implantation for the Treatment of Advanced Non-Small-cell Lung Cancer：analysis of Clinical Effect

Autologous Cytokine-Induced Killer Cell Therapy in Lung Cancer Patients: A Retrospective Study

Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer

The Effect of Icotinib Combined with Chemotherapy in Untreated Non-Small-cell Lung Cancer That Harbored EGFR-sensitive Mutations in a Real-Life Setting: a Retrospective Analysis